Research Article
The Clinical Relevance of IL-17-Producing CD4+CD161+ Cell and Its Subpopulations in Primary Sjögren’s Syndrome
Table 2
Clinical and laboratory characteristics of pSS patients with the higher or lower percentages of circulating CD4+CD161+ T cell subsets.
| | Characteristics | CD4+CD25+CD161+ T (%) | | value | CD4+CD25−CD161+ T (%) | | value | CD4+CD161+ T (%) | | value | | ≤6.70%, | >6.70%, | ≤17.79%, | >17.79%, | ≤17.66%, | >17.66%, |
| | Xerophthalmia (%) | 11 (92) | 39 (85) | 0.021 | 0.884 | 32 (91) | 18 (78) | 1.068 | 0.301 | 32 (89) | 18 (82) | 0.133 | 0.715 | | Xerostomia (%) | 12 (100) | 42 (91) | | 0.571 | 34 (97) | 20 (87) | 0.937 | 0.333 | 35 (97) | 19 (86) | 1.102 | 0.294 | | Parotid gland enlargement (%) | 2 (17) | 4 (9) | 0.076 | 0.783 | 4 (11) | 2 (9) | 0.000 | 1.000 | 5 (14) | 1 (5) | 0.475 | 0.491 | | Swollen and/or tender joints (%) | 3 (25) | 11 (24) | 0.000 | 1.000 | 8 (23) | 6 (26) | 0.079 | 0.779 | 9 (25) | 5 (23) | 0.039 | 0.844 | | Interstitial lung diseases (%) | 4 (33) | 15 (33) | 0.000 | 1.000 | 13 (37) | 6 (26) | 0.770 | 0.380 | 15 (42) | 4 (18) | 3.419 | 0.064 | | Leucopenia (%) | 3 (27) | 11 (26) | 0.000 | 1.000 | 8 (25) | 6 (27) | 0.035 | 0.851 | 7 (21) | 7 (33) | 0.982 | 0.322 | | Anaemia (%) | 4 (36) | 13 (30) | 0.001 | 0.979 | 8 (25) | 9 (41) | 1.530 | 0.216 | 10 (30) | 7 (33) | 0.055 | 0.815 | | Thrombocytopenia (%) | 1 (9) | 15 (35) | 1.695 | 0.193 | 7 (22) | 9 (41) | 2.265 | 0.132 | 7 (21) | 9 (43) | 2.884 | 0.089 | | ANA(+) (%) | 9 (75) | 41 (89) | 0.631 | 0.427 | 28 (80) | 22 (96) | 1.695 | 0.193 | 29 (81) | 21 (95) | 1.450 | 0.228 | | Anti-SSA(+) (%) | 10 (83) | 35 (76) | 0.022 | 0.883 | 26 (74) | 19 (83) | 0.553 | 0.457 | 28 (78) | 17 (77) | 0.000 | 1.000 | | Anti-SSB(+) (%) | 4 (33) | 15 (33) | 0.000 | 1.000 | 11 (31) | 8 (35) | 0.071 | 0.790 | 12 (33) | 7 (32) | 0.014 | 0.905 | | Anti-α-Fodrin(+) (%) | 0 (0) | 2 (4) | | 1.000 | 1 (3) | 1 (4) | | 1.000 | 1 (3) | 1 (5) | | 1.000 | | RF(+) (%) | 7 (58) | 24 (52) | 0.145 | 0.703 | 15 (43) | 16 (70) | 3.979 | 0.046 | 16 (44) | 15 (68) | 3.092 | 0.079 | | Decreased C3 (%) | 6 (50) | 21 (46) | 0.072 | 0.788 | 8 (23) | 8 (35) | 0.988 | 0.320 | 10 (28) | 6 (27) | 0.002 | 0.967 | | Decreased C4 (%) | 1 (8) | 13 (28) | 1.119 | 0.290 | 7 (20) | 7 (30) | 0.825 | 0.364 | 8 (22) | 6 (27) | 0.190 | 0.663 | | Increased ESR (%) | 6 (55) | 24 (53) | 0.005 | 0.942 | 12 (36) | 18 (78) | 9.565 | 0.002 | 14 (41) | 16 (73) | 5.346 | 0.021 | | Increased CRP (%) | 0 (0) | 5 (11) | 0.381 | 0.537 | 3 (9) | 2 (9) | 0.000 | 1.000 | 3 (8) | 2 (9) | 0.000 | 1.000 | | Increased IgA (%) | 5 (42) | 10 (22) | 1.069 | 0.301 | 9 (26) | 6 (26) | 0.001 | 0.975 | 10 (28) | 5 (23) | 0.182 | 0.670 | | Increased IgG (%) | 6 (50) | 22 (48) | 0.018 | 0.893 | 16 (46) | 12 (52) | 0.232 | 0.630 | 18 (50) | 10 (45) | 0.113 | 0.737 | | Increased IgM (%) | 1 (8) | 4 (9) | 0.000 | 1.000 | 2 (3) | 6 (13) | 0.245 | 0.621 | 4 (11) | 1 (5) | 0.146 | 0.702 | | Increased γ-globulin (%) | 8 (67) | 30 (65) | 0.000 | 1.000 | 20 (57) | 18 (78) | 2.740 | 0.098 | 22 (61) | 16 (73) | 0.816 | 0.366 |
|
|
pSS: primary Sjögren’s syndrome; ANA: antinuclear antibodies; Anti-SSA: anti-Ro/SSA antibody; Anti-SSB: anti-La/SSB antibody; RF: rheumatoid factor; C3: complement component C3; C4: complement component C4; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; IgA: immunoglobulin A; IgG: immunoglobulin G; IgM: immunoglobulin M (IgM). The values in bold represent ones with statistical significance.
|
